January 15, 2019 06:14 AM EST

Merck highlights crucial hit for Keytruda in second-line esophageal carcinoma — but there are also 2 misses

Amber Tong

Merck has unveiled a Phase III data package backing Keytruda’s case as a second-line treatment for the tough indications of esophageal and esophagogastric junction carcinoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck highlights crucial hit for Keytruda in second-line esophageal carcinoma — but there are also 2 misses

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Mer­ck high­lights cru­cial hit for Keytru­da in sec­ond-line esophageal car­ci­no­ma — but there are al­so 2 miss­es

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Merck highlights crucial hit for Keytruda in second-line esophageal carcinoma — but there are also 2 misses

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial